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Objective: To report side effects seen in a clinical cohort of patients aged 65 years with 
rheumatoid arthritis (RA) treated with the tumor necrosis factor-α TNF-α blocker etanercept 
and to compare the side effects rate with patients aged 65 years.
Methods: All patients with RA that started etanercept and who were referred to our rheuma-
tology unit from November 2005 to March 2009 were included in this study and prospectively 
followed to collect side effects related to therapy.
Results: One hundred three patients were enrolled: 41 (37 females, 4 males) aged 65 years 
and 62 (40 females, 22 males) aged 65 years. In the patients aged 65 years, the safety profile 
(defined as rate of side effects) of etanercept was similar to that in patients aged 65 years 
(P  0.05) and the survival curves between the groups were similar (P  0.05).
Conclusions: In our three-year experience, the anti-TNFα agent etanercept has been well 
tolerated and safe in elderly patients. The risk of side effects in these patients was no greater 
than in subjects aged 65 years. However, such inhibitors are associated with various and 
numerous side effects and elderly patients with RA should be carefully monitored to limit the 
risk of side effects during anti-TNFα therapy as much as possible.
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Introduction
Rheumatoid arthritis (RA) is an erosive disease that predominantly involves the 
synovial tissue of joints and is characterized by variable disease onset and clinical 
course, potentially resulting in structural joint destruction and subsequent permanent 
disability.1
Epidemiological studies have shown that RA is most prevalent in those who 
are aged 65 years or older.2,3 The disease is commonly diagnosed between the ages 
of 30 and 50 years, but up to 33% of subjects may be diagnosed after the age of 
60 years. Despite the high prevalence of RA in the elderly, and the likelihood that 
older patients have adverse reactions to medications as a result of age-related changes 
in drug metabolism and the presence of comorbid illnesses requiring concomitant 
medications, patients older than 65 years tend to be inadequately represented in RA 
clinical trials.5,6 Also, the tolerability of and response to therapy in these patients 
as a group has not been studied in detail. In one retrospective analysis of disease-
modifying antirheumatic drugs (DMARDs) including gold, D-penicillamine, 
azathioprine, and methotrexate (MTX), a substantially higher withdrawal rate due 
to toxicity was observed in patients older than 65 years compared to those younger 
than 65 years.5Biologics: Targets & Therapy 2010:4 
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Etanercept is a recombinant human fusion protein that 
inhibits the activity of tumor necrosis factor (TNF) and 
lymphotoxin-α. In clinical trials of RA, etanercept alone or 
in combination with MTX was well tolerated and produced 
significant sustained improvement in disease activity in 
patients with long-standing RA who failed multiple DMARDs 
and in patients with early aggressive disease who never 
received MTX.6–10 Etanercept is effective in inhibiting radio-
graphic progression in patients with RA; 72% of patients with 
early aggressive RA who received 25 mg etanercept mono-
therapy had no new radiographic erosions during one year of 
treatment.10 In these clinical trials, the response to etanercept 
therapy in elderly patients was not described in detail.
The aim of our study was to assess whether the use of 
etanercept is associated with a different rate of adverse events 
in elderly versus younger RA subjects and whether the drug 
survival curves are different in the two groups.
Materials and methods
Subjects with RA (American College of Rheumatology 
criteria11) that started etanercept from November 2005 to 
March 2009 and referring to our rheumatology unit were 
included in this study and prospectively followed. The 
etanercept dose was 50 mg subcutaneously once a week. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) and 
corticosteroids, if needed, MTX, or other previous DMARDs, 
if tolerated, were continued. A complete physical examina-
tion, standard laboratory tests, were assessed at baseline 
and either every two months thereafter. At the screening 
visit a chest X-ray, an electrocardiogram (EKG), a tuber-
culin skin test were performed and a complete hematic 
biometry analysis (complete blood count, C-reactive protein, 
erythrocyte sedimentation rate, creatinine, prostate-specific 
antigen total and free, aspartate aminotransferase and alanine 
aminotransferase, antinuclear antibodies, urinalysis). Patients 
aged 65 years also received an abdominal ecography, a 
mammography, three serial stool blood tests, and serum 
electrophoresis. A previous malignancy, history of cardiac 
failure with New York Heart Association (NYHA) class 3, 
or clinical findings suspect for malignancies at the study 
screening were used as exclusion criteria. Safety profile 
points included incidence rates of all side effects (SEs) 
defined as: adverse events (AE, with a temporary therapy 
suspension), serious AE (SAE, defined as an AE that required 
the definitive discontinuation of the therapy and hospitaliza-
tion, malignancies, and deaths), infectious diseases (IAE, 
with temporary or definitive therapy suspension associated 
with intravenous antibiotic treatment).
statistical analysis
Pairwise comparisons were based on the Wilcoxon matched 
pairs signed-ranks test. The safety profile in the two groups 
was estimated by survival analysis, taking any AE as the event 
of interest using the Kaplan–Meier method. Comparisons 
between the resultant curves were made by log rank test. 
All values of 0.05 were considered to indicate statistical 
significance (two-tailed test).
Results
One hundred three caucasian patients out of 254 were 
eligible: 41 (37 females, 4 males) aged 65 years and 62 
(40 females, 22 males) aged 65 years. Mean disease onset 
age was 57.4 ± 1.7 years in younger and 60.4 ± 3.2 years in 
older patients (P  0.05). Mean age at beginning of TNF 
blocker was 57.8 ± 6.9 years in younger and 68.2 ± 3.2 years 
in older patients (P  0.05). The duration of the anti-TNF 
treatment was 29.4 ± 11.2 and 27.9 ± 3.3 months, respec-
tively (P  0.05). In the whole population, 35 SEs (33.98% 
of cases) that led to temporary/permanent withdrawal were 
observed (9 AEs, 20 IAEs, 6 SAEs). The rate of patients 
presenting SEs was 41.4% of patients aged 65 years 
versus 30.6% of patients aged 65 years (P = 0.318; 
Table 1). The survival curves of these two groups were no 
significantly different (Mantel–Cox log rank test, P = 0.267; 
Figure 1).
Table  number of adverse events in the groups
65 years old  
patients #6
65 year old   
patients #4
# Adverse events (AEs)
Fever 2 4
Local reaction 1 0
Flu 2 1
# Infectious diseases (IAE)
Lower Urinary tract infections 3 2
Upper Respiratory tract infection 3 5
Tonsillitis 1 0
Discitis 1 0
Mycotic infection 1 1
herpes virus infection 3 0
Serious adverse events (SAEs)
squamocellular carcinoma 0 1
MgUs 2 1
cardiac failure 0 1
Myocardial infarction 0 1
Total AEs 9 7Biologics: Targets & Therapy 2010:4 
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Discussion
Rheumatoid arthritis is a chronic illness characterized by 
inflammation of the synovial tissue in joints, which can lead 
to joint destruction. RA affects around 0.5%–1% of the 
population, three times as many women as men, and has 
a peak age of onset between the ages of 40 and 70 years. 
The prevalence of the disease at the age of 65 years is six 
times the prevalence at the age of 25 years. RA is a major 
cause of disability and institutionalization in an aging 
population.12 The joint pain and swelling that are charac-
teristic of RA often impairs mobility and the performance 
of activities of daily living, resulting in difficulties in 
self-care, diminished independence, and reduced involve-
ment in family, work, and social roles.13,14 The influence 
on functional status is especially critical in older patients 
with RA, who also tend to have a higher frequency of acute 
onset and weight loss at presentation and are more likely 
than younger patients to have large joint involvement.15 
Some studies have suggested that RA is more aggressive in 
the elderly, is associated with more radiographic damage, 
and may result in more rapid functional decline than in 
younger patients.16
Special issues confound the choice of therapy for 
elderly patients. In general, older patients are more likely 
to have concomitant illness including malignancies and 
cardiovascular disease. Additionally, they are more suscep-
tible to serious infections and mortality from infections. 
Medication compliance, drug interactions, and decreased 
tolerability complicate the management of older patients. 
The older RA patient is likely to require multiple medi-
cations and have difficulties with drug compliance, and 
may be prone to commit dosage errors. Physiological 
factors in the elderly may modify pharmacokinetics, 
tissue responsiveness, and homeostatic mechanisms.17–19 
These factors may contribute to differences in toxicity 
and efficacy among different age groups in patients with 
RA. We observed no consistent differences in the rates 
or types of adverse events between the age groups in this 
study, which suggests that treatment with etanercept does 
not increase the risk of these events in the elderly popula-
tion beyond the increases inherent with advanced age and 
comorbidities.
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Figure  survival curves for older and younger patients (P  0.05).Biologics: Targets & Therapy 2010:4
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